Thus, we conducted the present prospective, randomised, and controlled trial to assess the cardiac safety, as well as the therapeutic efficacy, of the concurrent administration of trastuzumab and anthracyclines in the adjuvant treatment of HER2-positive early breast cancer. This evidence concerns the gene ERBB2 and breast cancer.